Search research articles
Contact Us
Filters
Showing results (271-280 of 330) with videos related to
Page
of 33
Sort By:
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
September 25, 2007
Induction of autologous graft-versus-host disease: results of a randomized prospective clinical trial in patients with poor risk lymphoma
Javier Bolaños-Meade, Elizabeth Garrett-Mayer, Leo Luznik, et al.
Cancer Immunology, Immunotherapy : CII
|
October 28, 2016
Alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 1 can support immune responses toward tumors overexpressing ganglioside D3 in mice
Jonathan M Eby, Levi Barse, Steven W Henning, et al.
Clinical Pharmacology and Therapeutics
|
October 16, 2021
Real-world Overall Survival Using Oncology Electronic Health Record Data: Friends of Cancer Research Pilot
Laura Lasiter, Olga Tymejczyk, Elizabeth Garrett-Mayer, et al.
JCO Precision Oncology
|
June 14, 2023
Pertuzumab Plus Trastuzumab in Patients With Lung Cancer With <i>ERBB2</i> Mutation or Amplification: Results From the Targeted Agent and Profiling Utilization Registry Study
Apar K Ganti, Michael Rothe, Pam K Mangat, et al.
Journal of Leukocyte Biology
|
February 28, 2016
Hepatitis C virus-cross-reactive TCR gene-modified T cells: a model for immunotherapy against diseases with genomic instability
Timothy T Spear, Timothy P Riley, Gretchen E Lyons, et al.
JCO Precision Oncology
|
April 7, 2023
Pertuzumab Plus Trastuzumab in Patients With Endometrial Cancer With <i>ERBB2/3</i> Amplification, Overexpression, or Mutation: Results From the TAPUR Study
Eugene R Ahn, Michael Rothe, Pam K Mangat, et al.
JCO Precision Oncology
|
November 21, 2022
Cobimetinib Plus Vemurafenib in Patients With Colorectal Cancer With <i>BRAF</i> Mutations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study
Kelsey A Klute, Michael Rothe, Elizabeth Garrett-Mayer, et al.
JCO Precision Oncology
|
April 11, 2024
Regorafenib in Patients With Solid Tumors With <i>BRAF</i> Alterations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study
Vaibhav Sahai, Michael Rothe, Pam K Mangat, et al.
Targeted Oncology
|
October 22, 2020
Cetuximab in Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Ovarian Cancer Without KRAS, NRAS, or BRAF Mutations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study
Julie G Fisher, David Tait, Elizabeth Garrett-Mayer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 2, 2019
Comparative Assessment of Clinical Benefit Using the ESMO-Magnitude of Clinical Benefit Scale Version 1.1 and the ASCO Value Framework Net Health Benefit Score
Nathan I Cherny, Elisabeth G E de Vries, Urania Dafni, et al.
Page
of 33
Search research articles
Search
Showing results (271-280 of 330) with videos related to
Sort By:
Page
of 33
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
September 25, 2007
Induction of autologous graft-versus-host disease: results of a randomized prospective clinical trial in patients with poor risk lymphoma
Javier Bolaños-Meade, Elizabeth Garrett-Mayer, Leo Luznik, et al.
Cancer Immunology, Immunotherapy : CII
|
October 28, 2016
Alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 1 can support immune responses toward tumors overexpressing ganglioside D3 in mice
Jonathan M Eby, Levi Barse, Steven W Henning, et al.
Clinical Pharmacology and Therapeutics
|
October 16, 2021
Real-world Overall Survival Using Oncology Electronic Health Record Data: Friends of Cancer Research Pilot
Laura Lasiter, Olga Tymejczyk, Elizabeth Garrett-Mayer, et al.
JCO Precision Oncology
|
June 14, 2023
Pertuzumab Plus Trastuzumab in Patients With Lung Cancer With <i>ERBB2</i> Mutation or Amplification: Results From the Targeted Agent and Profiling Utilization Registry Study
Apar K Ganti, Michael Rothe, Pam K Mangat, et al.
Journal of Leukocyte Biology
|
February 28, 2016
Hepatitis C virus-cross-reactive TCR gene-modified T cells: a model for immunotherapy against diseases with genomic instability
Timothy T Spear, Timothy P Riley, Gretchen E Lyons, et al.
JCO Precision Oncology
|
April 7, 2023
Pertuzumab Plus Trastuzumab in Patients With Endometrial Cancer With <i>ERBB2/3</i> Amplification, Overexpression, or Mutation: Results From the TAPUR Study
Eugene R Ahn, Michael Rothe, Pam K Mangat, et al.
JCO Precision Oncology
|
November 21, 2022
Cobimetinib Plus Vemurafenib in Patients With Colorectal Cancer With <i>BRAF</i> Mutations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study
Kelsey A Klute, Michael Rothe, Elizabeth Garrett-Mayer, et al.
JCO Precision Oncology
|
April 11, 2024
Regorafenib in Patients With Solid Tumors With <i>BRAF</i> Alterations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study
Vaibhav Sahai, Michael Rothe, Pam K Mangat, et al.
Targeted Oncology
|
October 22, 2020
Cetuximab in Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Ovarian Cancer Without KRAS, NRAS, or BRAF Mutations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study
Julie G Fisher, David Tait, Elizabeth Garrett-Mayer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 2, 2019
Comparative Assessment of Clinical Benefit Using the ESMO-Magnitude of Clinical Benefit Scale Version 1.1 and the ASCO Value Framework Net Health Benefit Score
Nathan I Cherny, Elisabeth G E de Vries, Urania Dafni, et al.
Page
of 33